| Item type |
文献 / Documents(1) |
| 公開日 |
2023-04-14 |
| アクセス権 |
|
|
アクセス権 |
open access |
| 資源タイプ |
|
|
資源タイプ識別子 |
http://purl.org/coar/resource_type/c_6501 |
|
資源タイプ |
journal article |
| 出版社版DOI |
|
|
|
関連識別子 |
https://doi.org/10.3390/toxins14110739 |
|
|
関連名称 |
10.3390/toxins14110739 |
| 出版タイプ |
|
|
出版タイプ |
VoR |
|
出版タイプResource |
http://purl.org/coar/version/c_970fb48d4fbd8a85 |
| タイトル |
|
|
タイトル |
A Pilot Study of A2NTX, a Novel Low-Molecular-Weight Neurotoxin Derived from Subtype A2 for Post-Stroke Lower Limb Spasticity : Comparison with OnabotulinumtoxinA |
| 著者 |
梶, 龍兒
宮城, 愛
佐藤, 紀
フルモト, タイキ
タケウチ, トシアキ
宮本, 亮介
コウダ, トモコ
和泉, 唯信
コザキ, シュンジ
|
| 抄録 |
|
|
内容記述 |
All the currently used type A botulinum neurotoxins for clinical uses are of subtype A1. We compared the efficacy and safety for the first time head-to-head between a novel botulinum toxin A2NTX prepared from subtype A2 and onabotulinumtoxinA (BOTOX) derived from A1 for post-stroke spasticity. We assessed the modified Ashworth scale (MAS) of the ankle joint, the mobility scores of Functional Independence Measure (FIM), and the grip power of the unaffected hand before and after injecting 300 units of BOTOX or A2NTX into calf muscles. The procedure was done in a blinded manner for the patient, the injecting physician, and the examiner. Stroke patients with chronic spastic hemiparesis (15 for A2NTX and 16 for BOTOX) were enrolled, and 11 for A2NTX and 13 for BOTOX (MAS of ankle; > or = 2) were entered for the MAS study. Area-under-curves of changes in MAS (primary outcome) were greater for A2NTX by day 30 (p = 0.044), and were similar by day 60. FIM was significantly improved in the A2NTX group (p = 0.005), but not in the BOTOX group by day 60. The hand grip of the unaffected limb was significantly decreased in the BOTOX-injected group (p = 0.002), but was unaffected in the A2NTX-injected group by day 60, suggesting there was less spread of A2NTX to the upper limb than there was with BOTOX. Being a small-sized pilot investigation with an imbalance in the gender of the subjects, the present study suggested superior efficacy and safety of A2NTX, and warrants a larger scale clinical trial of A2NTX to confirm these preliminary results. |
| キーワード |
|
|
主題 |
botulinum neurotoxin |
| キーワード |
|
|
主題 |
subtype A2 |
| キーワード |
|
|
主題 |
A2NTX |
| キーワード |
|
|
主題 |
onabotulinumtoxinA |
| キーワード |
|
|
主題 |
clinical efficacy |
| キーワード |
|
|
主題 |
safety |
| キーワード |
|
|
主題 |
spasticity: modified Ashworth scale |
| キーワード |
|
|
主題 |
Functional Independence Measure |
| キーワード |
|
|
主題 |
hand grip |
| キーワード |
|
|
主題 |
spread |
| 書誌情報 |
en : Toxins
巻 14,
号 11,
p. 739,
発行日 2022-10-28
|
| 収録物ID |
|
|
収録物識別子タイプ |
ISSN |
|
収録物識別子 |
20726651 |
| 出版者 |
|
|
出版者 |
MDPI |
| 権利情報 |
|
|
権利情報 |
This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
| EID |
|
|
識別子 |
394090 |
| 言語 |
|
|
言語 |
eng |
toxins_14_11_739.pdf (2.27 MB)
.png)
